Patents Examined by Nissa M Westerberg
  • Patent number: 10307352
    Abstract: A composition including water, about 0.1% to about 0.4% of a 4-substituted resorcinol, an ester having at least about 25 carbon atoms, and a polymeric emulsifier is provided. The composition comprises less than about 5% by weight of oils and is substantially free of monomeric emulsifier. Methods of treating the skin are also provided.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: June 4, 2019
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Marisa DeVita Dufort, Simarna Kaur, Michael D. Southall, Ping Wen, Jeffrey M. Wu
  • Patent number: 10294107
    Abstract: The invention relates to hardenable ceramic bone substitute compositions having improved setting, powders for such compositions and methods for their manufacture and use in medical treatment. More specifically the invention relates to hardenable bone substitute powder and hardenable bone substitute paste with improved setting properties, comprising calcium sulfate and heat-treated hydroxyapatite (passivated HA), which bone substitute is suitable for treatment of disorders of supportive tissue such as bone loss, bone fracture, bone trauma and osteomyelitis.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: May 21, 2019
    Assignee: Bone Support AB
    Inventors: Kristina Caroline Victoria Ehrenborg, Veronica Rebecca Sandell, Eva Christina Lidén
  • Patent number: 10251393
    Abstract: A synthetic polymer film includes a surface which has a plurality of raised portions. A two-dimensional size of the plurality of raised portions is in a range of more than 20 nm and less than 500 nm when viewed in a normal direction of the synthetic polymer film. The surface has a microbicidal effect. Further, a concentration of a nitrogen element included in the surface is not less than 0.7 at %.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: April 9, 2019
    Assignee: Sharp Kabushiki Kaisha
    Inventors: Miho Yamada, Kiyoshi Minoura, Takahiro Nakahara, Ken Atsumo
  • Patent number: 10213443
    Abstract: The invention relates to a topical suspension formulation that includes a tetracycline, a liquid medium and a polymeric gelling agent. The tetracycline may be in the form of its pharmaceutically acceptable salts, hydrates, or polymorphs and is in a suspended form within the formulation. The liquid medium is selected such that it does not dissolve or substantially minimally dissolves the tetracycline. The gelling agent is a polymeric hydrocarbon gelling agent. Preferably, the tetracycline has a particle size of less than or equal to about 20 microns.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: February 26, 2019
    Assignee: Hovione Scientia Limited
    Inventors: Mohammad Salman, Arturo Angel, Vijaya Swaminathan, George Magrath
  • Patent number: 10182990
    Abstract: Gastric resistant film-forming compositions are described herein. The composition contains a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (SOFLET®) containing an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition. The compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form and esophageal irritation due to the reflux of irritant drugs delivered orally.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: January 22, 2019
    Assignee: Patheon Softgels Inc.
    Inventor: Nachiappan Chidambaram
  • Patent number: 10172773
    Abstract: Disclosed is a method of reducing or avoiding staining in or on clothing caused by a cosmetic or dermatological preparation comprising one or more antiperspirant substances and/or of improving the ability of stains in or on clothing which are caused at least in part by said preparation to be washed out from the clothing. The method comprises including in the preparation one or more cationic surfactants.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: January 8, 2019
    Assignee: Beiersdorf AG
    Inventors: Michael Urban, Heike Miertsch, Stefan Biel, Sabine Kuehne, Stefan Bruening, Rolf Kawa
  • Patent number: 10172954
    Abstract: The present invention relates to reverse-micellar systems comprising at least an active agent, an acylglycerol, a sterol, lecithin, ethanol and water, for use in chelation and/or sequestering of a radionuclide and/or a metal in a patient. The invention also relates to the reverse-micellar systems and to pharmaceutical compositions comprising said reverse-micellar systems.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: January 8, 2019
    Assignee: MEDESIS PHARMA
    Inventors: Caroline Bauer, Elsa Compte, Olivier Gremy, Laurent Miccoli, Jaime Francisco Angulo-Mora, Jean-Claude Maurel
  • Patent number: 10144204
    Abstract: Substrate comprising a discrete first layer comprising a first surface, an opposing second surface and a polymeric first material, wherein the first layer has a thickness of from about 1 micron to about 1000 microns and a hardness of from about 10 to about 80 on the Shore A scale; a discrete second layer comprising a first surface, an opposing second surface, and a second material, wherein the second layer has a hardness of from about 1 to about 70 on the Shore OOO scale and a thickness of from about 0.001 cm to about 2.
    Type: Grant
    Filed: January 8, 2007
    Date of Patent: December 4, 2018
    Assignee: The Procter & Gamble Company
    Inventors: Pankaj Yadav Patil, Richard Tweddell, III, Saswati Datta
  • Patent number: 10130655
    Abstract: This invention provides a pre-surgical disinfecting composition that includes at least about 50 percent by weight of a C1-6 alcohol, based upon the total weight of the disinfecting composition, an acid, and a cationic oligomer or polymer. A method for pre-surgical skin disinfection with rapid antiseptic efficacy without the use of secondary antimicrobial compounds is also described.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: November 20, 2018
    Assignee: GOJO Industries, Inc.
    Inventors: David R. Macinga, Marcia Snyder, James W. Arbogast
  • Patent number: 10123977
    Abstract: A gel patch includes a base fabric, an adhesive layer, and a release liner in this order, wherein the adhesive layer contains a physiologically active substance, a water-soluble (meth)acrylic polymer, water, a surfactant, and poly(methyl acrylate/2-ethylhexyl acrylate), and the surfactant comprises a polyethylene glycol fatty acid ester or a polyoxyethylene sorbitan fatty acid ester.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: November 13, 2018
    Assignee: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Keiichiro Tsurushima, Yasuhisa Kose, Takaaki Yoshinaga
  • Patent number: 10111818
    Abstract: Disclosed is cosmetic or dermatological preparation which comprises one or more antiperspirant substances and one or more cationic surfactants.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: October 30, 2018
    Assignee: BEIERSDORF AG
    Inventors: Michael Urban, Heike Miertsch, Stefan Biel, Sabine Kuehne, Stefan Bruening, Rolf Kawa
  • Patent number: 10105300
    Abstract: Disclosed is cosmetic or dermatological preparation which is present as an aerosol spray and comprises one or more antiperspirant substances and one or more cationic surfactants.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: October 23, 2018
    Assignee: BEIERSDORF AG
    Inventors: Michael Urban, Heike Miertsch, Stefan Biel, Sabine Kuehne, Stefan Bruening, Rolf Kawa
  • Patent number: 9913917
    Abstract: The invention relates to highly fluorescent metal oxide nanoparticles to which biomolecules and other compounds can be chemically linked to form biocompatible, stable optical imaging agents for in vitro and in vivo applications. The fluorescent metal oxide nanoparticles may also be used for magnetic resonance imaging (MRI), thus providing a multi modality imaging agent.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: March 13, 2018
    Assignee: VisEn Medical, Inc.
    Inventors: Kevin Groves, Milind Rajopadhye
  • Patent number: 9907866
    Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: March 6, 2018
    Assignee: GUERBET
    Inventors: Dominique Meyer, Claire Corot, Marc Port, Vincent Barbotin, Bruno Bonnemain
  • Patent number: 8349293
    Abstract: The invention relates to the use of metal nanoparticles for the preparation of a composition for diagnosing Alzheimer's disease by MRI.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: January 8, 2013
    Assignee: Guerbet
    Inventor: Claire Corot
  • Patent number: 7931909
    Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: April 26, 2011
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, James A. Burke, Joan-En Chang-Lin
  • Patent number: 7910615
    Abstract: A prophylactic or therapeutic agent for diabetic maculopathy, which can be administered for a long time and exhibits efficacy in a mechanism different from that of existing medicines. The invention relates to a prophylactic or therapeutic agent for diabetic maculopathy, comprising, as an active ingredient, a compound represented by the general formula: wherein X represents a halogen or a hydrogen atom, R1 and R2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle. Preferably, the compound is (2S,4S)-6-fluoro-2?,5?-dioxospiro[chroman-4,4?-imidazolidine]-2-carboxamide. The invention also provides a model animal with diabetic maculopathy produced by subjecting a diabetic animal to intraocular ischemia/reperfusion to express edema in a retinal visual cell layer or in a macula lutea.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: March 22, 2011
    Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.
    Inventors: Noriaki Kato, Hiroshi Nagano, Kaori Taniko, Takahito Jomori
  • Patent number: 7897586
    Abstract: A stable anaesthetic composition is described which is particularly suitable for use in cats and dogs. The composition comprises an aqueous solution of an anaesthetically effective amount of a water soluble cyclodextrin or a cyclodextrin derivative complex of alfaxalone and a buffer, excluding phosphate buffer pH 7.0, 0.1M mixed as defined in the British Pharmacopoeia 1998, such that the pH of the solution is from 6.0-8.0.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: March 1, 2011
    Assignee: Jurox Pty. Ltd.
    Inventors: Peter John Kieran, Kai Kin Lau, Barry Edward Patten
  • Patent number: 7846481
    Abstract: Perfuming or flavoring microcapsules that include, further to a perfuming or flavoring ingredient and a carrier material, an explosion suppressant, proved to undergo, when suspended in hot air during their preparation, an explosion of a reduced violence. The explosion suppressant is selected from C1 to C12 carboxylic acids, their salts and mixtures of these.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: December 7, 2010
    Assignee: Firmenich SA
    Inventors: Gil Trophardy, Glenn Paul Johannes Verhovnik
  • Patent number: 7825153
    Abstract: A low concentration formulation for hydrophobic photosensitizers (PS) and method for photodynamic therapy (“PDT”) using the disclosed low concentration formulations provide for more accurate, more efficient and more convenient dosing. The inventive formulation (1) reduces the time for a therapeutically effective level of photosensitizer to accumulate in diseased tissue and (2) reduces the time for achieving a sufficient ratio of photosensitizer in diseased tissue vs. healthy tissue. The inventive formulation reduces the time interval between PS application/administration and irradiation (the drug-light interval or “DLI”) and can provide for a “same day” PDT treatment option. 0.08 mg/ml to 1.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: November 2, 2010
    Assignee: CeramOptec Industries, Inc.
    Inventors: Nikolay Nifantiev, Volker Albrecht